קפריסין - יוונית - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

dr. falk pharma gmbh (0000008100) leinenweberstr. 5, freiburg, d-79108 - ursodeoxycholic acid - oral suspension - 250mg/5ml - ursodeoxycholic acid (0000128132) 250mg - ursodeoxycholic acid

קפריסין - יוונית - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

dr. falk pharma gmbh (0000008100) leinenweberstr. 5, freiburg, d-79108 - ursodeoxycholic acid - capsule,hard - 250mg - ursodeoxycholic acid (0000128132) 250mg - ursodeoxycholic acid

קפריסין - יוונית - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

sandoz gmbh - valsartan - film coated tablets - 40mg - 8000001531 - valsartan - 40 mg - valsartan

קפריסין - יוונית - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

zentiva italia srl - valsartan - film coated tablets - 160mg - 8000001531 - valsartan - 160 mg - valsartan

קפריסין - יוונית - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

the star medicines importers co. ltd (0000003109) 10 loukis akritas str, lemesos, 3601, 50151 - saccharated iron oxide - solution for injection - 100mg/5ml - saccharated iron oxide (0008047674) 100mg - saccharated iron oxide

קפריסין - יוונית - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

glaxo group ltd - ΥΔΡΟΧΛΩΡΙΔΙΟ ΡΑΝΙΤΙΔΙΝΗΣ - film coated tablets - 150mg - 0066357593 - ranitidine hydrochloride - 168 mg - ranitidine

קפריסין - יוונית - Κυπριακή Δημοκρατία, Υπουργείο Γεωργίας, Αγροτικής Ανάπτυξης και Περιβάλλοντος, Κτηνιατρικές Υπηρεσίες

dox-al italia s.p.a - acetylsalicylic acid 800 g/kg - powder for oral use - anti-inflammatory analgesic antipyretic - cattle, calves, pigs, broilers, turkeys

יוון - יוונית - Εθνικός Οργανισμός Φαρμάκων

sandoz pharmaceuticals d.d. (abbr. sandoz d.d.), slovenia verovskova 57, si-1000 ljubljana +386 1 580 2111 - azacitidine - pd.inj.sus (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 100mg/vial (25mg/ml) - azacitidine 25mg - azacitidine

האיחוד האירופי - יוונית - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - Αντινεοπλασματικοί παράγοντες - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

האיחוד האירופי - יוונית - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Αντιθρομβωτικοί παράγοντες - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.